Clinical Trials and Medical Research for PsA
The first thing clinical trials offer patients is access to cutting-edge treatments. Clinical trials provide access to new medications and therapies before they are widely available to the public. These treatments may offer better symptom control, fewer side effects, or even more convenient dosing than standard options provide. Secondly, every participant helps researchers collect vital data that can improve the lives of millions of people with psoriatic arthritis. Your involvement can directly influence how psoriatic arthritis is treated in the future, benefiting not just yourself, but also others living with the disease.
Another bonus to being part of a clinical trial is you will be receiving close monitoring by health care professionals who are readily available. Participants in clinical trials are closely monitored by medical experts and can offer lots of advice and assistance. This additional attention often leads to better overall care, and more comprehensive disease tracking than some patients receive through pathways of standard treatment. In addition, participating in clinical trials can help increase diversity for many underrepresented groups. This can help to ensure that new treatments are effective across all ethnic, gender, and age groups.
Taking part in medical research and clinical trials can be extremely empowering. It allows patients to learn more about their condition, play an active role in their own health care, and stay informed about new and available treatment options. (As I always say, be your own patient advocate and ask about these trials at your doctor appointments!) Don't forget that before joining a clinical trial, it's important to weigh the potential benefits and risks. Always consult with your health care provider first. Participants should receive detailed information about the study's purpose, procedures, possible side effects, and their rights as a volunteer. Consulting with a trusted health care provider can definitely help determine whether a specific trial is a good fit for you.
Did you know that clinical trials are helping to pave the way for the next generation of psoriatic disease treatment options? Did you also know you can learn how to participate in them through your doctor's office? Many patients don't even know that there are many clinical trials available. Patients interested in learning more about clinical trials, especially those related to psoriatic arthritis, have several trusted resources available.
Here are some clinical trial and medical research resources:
The National Psoriasis Foundation: This is a trusted advocacy group for people with psoriasis and psoriatic arthritis. It's helpful because it provides a curated list of psoriatic disease clinical trials and educational resources for participants that are currently taking place. I check this site regularly to learn more about new and upcoming treatment options as well.
ClinicalTrials.gov: This website is the U.S. National Library of Medicine's database of privately and publicly funded clinical studies around the world. You can search by condition ('psoriatic arthritis'), by your location, by your age group, and more.
CenterWatch: This site is a great resource for patients and provides information about new and upcoming clinical trials. It offers detailed listings, lots of patient education materials, and even up-to-date clinical trial results.
Local academic medical centers and rheumatology clinics: Major hospitals and universities often have a ton of ongoing clinical trials. You may even be asked if you are in the hospital if you'd like to participate in medical research or a clinical trial. (This has happened to me a few times.) Your rheumatologist or care team may be aware of studies recruiting near you and will provide you with information regarding them.
Living with psoriatic arthritis can be challenging enough, but the progress being made in medical research is offering us new hope. Participating in clinical trials not only opens doors to promising treatments, but it plays a critical role in the advancement of care for everyone affected by PsA. By contributing to research, patients become key partners in shaping the future of health care. If you or someone you know is living with psoriatic arthritis, consider exploring local or national clinical trials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Astrana Health completes acquisition of Prospect Health for $708m
US-based Astrana Health has closed its acquisition of Prospect Health, a care delivery network, for a total purchase price of $708m. With a network of more than 11,000 providers, Prospet Health offers coordinated care to approximately 600,000 members. The network covers various states in the US, including Arizona, Rhode Island, Southern California, and Texas, serving Medicaid, Medicare Advantage, and Commercial business lines. Prospect Health's operations include a health plan, a management services organisation, a speciality pharmacy, and an acute care hospital. The acquisition price reflects a decrease from the initially stated $745m in November 2024. Astrana president and CEO Brandon Sim said: "We are excited to welcome Prospect Health's physicians, providers, and team members to Astrana Health. "Together, we will further accelerate our mission to drive consistent, coordinated, high-quality patient outcomes at scale, ultimately driving greater value across the healthcare ecosystem." Astrana projects that Prospect Health will contribute a total revenue of approximately $1.2bn and $81m in adjusted EBITDA annually. In addition, Astrana anticipates achieving $12m to $15m of synergies within the next one to one-and-a-half years. The company has updated its 2025 full-year guidance to a revenue range of $3.1bn to $3.3bn and adjusted EBITDA between $215m and $225m, considering Prospect Health's half-year contribution. Following the transaction, Astrana's net debt is expected to be approximately $700m. The company's management is focused on lessening the net leverage ratio to below 2.5 times within the next one to one-and-a-half years. Truist Securities led a consortium of banks that offered the term loan for the purchase. J P Morgan acted as the exclusive financial adviser to Astrana during the transaction. The acquisition follows Astrana's previous acquisition of Collaborative Health Systems in October last year, which also aimed to broaden its care delivery capabilities. "Astrana Health completes acquisition of Prospect Health for $708m" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal
-- Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion partnership deal. According to the report, AstraZeneca is considering a licensing agreement for Summit's ivonescimab lung cancer treatment. The deal structure could include a multi-billion dollar upfront payment followed by milestone payments that could bring the total value to approximately $15 billion over time. Summit has also reportedly been in talks with other major pharmaceutical companies about the experimental cancer drug, suggesting competitive interest in the treatment. The negotiations are still ongoing, and terms are being finalized, though the discussions could still fall apart or Summit might choose a different partner. Related articles Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal What could a shift in Intel's foundry strategy bring? Growth funds favor Makemytrip and SK Hynix: BofA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Lizzo Fires Back at Ozempic Critics: ‘This S**t Is Hard'
Lizzo is once again hitting back at busybodies and skeptics who won't stop speculating on her weight loss. In an interview with Women's Health, the 37-year-old singer aimed to make her mindset, motivation, and methods crystal clear. She directed some comments at those who, despite her previous statements, insist that Lizzo's changing figure is attributed to GLP-1 drugs. Lizzo shared with writer Jessica Herndon that she's recently received questions from fans, like, 'Are you taking Ozempic?' and 'What happened when you said it's okay to be fat?' This is not to say that the artist seeks to shade those who turn to GLP-1 drugs in their healthcare journeys. She said, 'If I did all of this on Ozempic....I would be just as proud of myself, because this s**t is hard.' For the 'About Damn Time' singer, this wasn't a weight loss journey, but a weight release journey. Because, as Lizzo sees it, she didn't actually lose anything. 'It's okay to release weight...[and] it's okay to gain weight after you've released weight,' she says. In January, Lizzo posted photos to her Instagram wearing workout gear paired with an ecstatic caption. 'I reached my weight release goal,' she wrote, adding a motivational message for fans about achieving their own goals. 'I wanted to be 'big-girl skinny,'' she tells Women's Health. 'Every big girl knows what I'm talking about. Big-girl skinny is 250 pounds.' This meant a balance of feeling like herself while reducing back pain and health concerns she struggled with. The change, she explains, came from consistent exercise and a nutritious diet with lean proteins and vegetables. Each week, she performs a mix of strength training and cardio for three days, and dedicates two days to 45-minute cardio workouts. It wasn't about chasing thinness—only feeling better in her body, on her terms.
